A detailed history of High Mark Wealth Management LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, High Mark Wealth Management LLC holds 91,196 shares of AUPH stock, worth $662,082. This represents 0.31% of its overall portfolio holdings.

Number of Shares
91,196
Previous 75,196 21.28%
Holding current value
$662,082
Previous $376,000 38.3%
% of portfolio
0.31%
Previous 0.23%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$4.81 - $5.78 $76,960 - $92,480
16,000 Added 21.28%
91,196 $520,000
Q1 2024

Apr 26, 2024

BUY
$4.93 - $9.31 $10,831 - $20,454
2,197 Added 3.01%
75,196 $376,000
Q4 2023

Jan 22, 2024

BUY
$7.13 - $9.49 $92,690 - $123,370
13,000 Added 21.67%
72,999 $656,000
Q3 2023

Oct 18, 2023

SELL
$7.77 - $12.27 $19,425 - $30,675
-2,500 Reduced 4.0%
59,999 $466,000
Q2 2023

Jul 26, 2023

SELL
$8.96 - $11.69 $17,920 - $23,380
-2,000 Reduced 3.1%
62,499 $604,000
Q1 2023

Apr 20, 2023

BUY
$5.94 - $11.27 $160,380 - $304,290
27,000 Added 72.0%
64,499 $706,000
Q1 2022

Apr 25, 2022

SELL
$10.05 - $22.48 $130,650 - $292,240
-13,000 Reduced 25.74%
37,499 $464,000
Q4 2021

Jan 20, 2022

SELL
$17.78 - $33.08 $1,244 - $2,315
-70 Reduced 0.14%
50,499 $1.16 Million
Q3 2021

Nov 01, 2021

BUY
$10.93 - $23.55 $35,139 - $75,713
3,215 Added 6.79%
50,569 $1.12 Million
Q2 2021

Aug 02, 2021

BUY
$10.0 - $14.52 $473,540 - $687,580
47,354 New
47,354 $614,000
Q1 2021

Apr 22, 2021

SELL
$12.3 - $18.73 $200,071 - $304,662
-16,266 Closed
0 $0
Q3 2020

Oct 26, 2020

SELL
$13.19 - $16.66 $9,892 - $12,495
-750 Reduced 4.41%
16,266 $240,000
Q1 2020

Apr 30, 2020

SELL
$11.34 - $21.46 $3,402 - $6,438
-300 Reduced 1.73%
17,016 $246,000
Q4 2019

Mar 19, 2020

BUY
$3.88 - $21.42 $67,186 - $370,908
17,316 New
17,316 $350,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.03B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track High Mark Wealth Management LLC Portfolio

Follow High Mark Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Mark Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Mark Wealth Management LLC with notifications on news.